<DOC>
	<DOCNO>NCT01458054</DOCNO>
	<brief_summary>This study Phase I open label drug interaction study evaluate effect omeprazole ritonavir GSK2336805 .</brief_summary>
	<brief_title>Effect Omeprazole Ritonavir GSK2336805 Pharmacokinetics Healthy Adults</brief_title>
	<detailed_description>This study Phase I open label drug interaction study two objective . The first objective study ( Cohort 1 ) determine pharmacokinetics single dose GSK2336805 affect co-administration repeat dos omeprazole , proton-pump inhibitor commonly use chronic hepatitis C patient . The second objective study ( Cohort 2 ) determine pharmacokinetics single dose GSK2336805 affect co-administration repeat dose ritonavir , HIV protease inhibitor drug potent inhibitor CYP 3A4 .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin great equal 1.5x Upper Limit Normal ( ULN ) ( isolated bilirubin great 1.5xULN acceptable bilirubin fractionate direct bilirubin less than35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Subjects value outside normal range always exclude enrollment . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation , oophorectomy , hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication follow visit . Body weight great equal 50 kilogram men great equal 45 kilogram woman . Body mass index ( BMI ) 18.532 inclusive allow ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB le 450 ; QTc le 480 subject Bundle Branch Block The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 milliliter within 56 day period . Pregnant female determine positive serum urine human chorionic gonadotropin test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . History regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . The subject 's systolic blood pressure outside range 90140 , diastolic blood pressure outside range 4590 heart rate outside range 50100 beat per minute ( bpm ) female subject 45100 beat per minute male subject . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) : Heart rate le 45 great 100 bpm men le 50 great 100 bpm woman . PR interval le 120 great 220 . QRS duration le 70 great 120 . QTc interval great 450 . Evidence previous myocardial infarction ( Does include ST segment change associate repolarization ) . Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , Wolf Parkinson White [ WPW ] syndrome ) . Sinus Pauses great 3 second . Any significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject . Nonsustained sustain ventricular tachycardia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>omeprazole</keyword>
	<keyword>ritonavir</keyword>
	<keyword>healthy subject</keyword>
	<keyword>drug interaction</keyword>
</DOC>